Format

Send to

Choose Destination
Mol Med. 2018 Sep 24;24(1):50. doi: 10.1186/s10020-018-0051-4.

Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics.

Author information

1
Department of Medicine, Hofstra-Northwell School of Medicine, Hempstead, USA.
2
Division of Hematology and Medical Oncology, Hofstra-Northwell School of Medicine, Hempstead, USA.
3
Department of Medicine, Hofstra-Northwell School of Medicine, Hempstead, USA. nseetharamu@northwell.edu.
4
Division of Hematology and Medical Oncology, Hofstra-Northwell School of Medicine, Hempstead, USA. nseetharamu@northwell.edu.

Abstract

Antibody-based therapy has revitalized the world of cancer therapeutics since rituximab was first approved for the treatment of Non-Hodgkin's Lymphoma. Monoclonal antibodies against cancer antigens have been successful strategies for only a handful of cancer types due to many reasons including lack of antibody specificity and complex nature of tumor milieu which interfere with antibody efficacy. Polyspecific antibodies are promising class of anti-cancer agents which can be directed at multiple tumor antigens to eradicate tumor cells more precisely and effectively. They may overcome some of these limitations and have already changed treatment landscape for some malignancies such as B cell acute lymphoblastic leukemia. Pre-clinical studies and early phase clinical trials have demonstrated that this approach may be an effective strategy even for solid tumors. This review focuses on the development of bispecific and trispecific antibody therapy for the treatment of solid tumor malignancies and highlights the potential they hold for future therapies to come.

KEYWORDS:

Bispecific antibody; Immunotherapy; Solid tumor; Trispecific antibody

PMID:
30249178
PMCID:
PMC6154901
DOI:
10.1186/s10020-018-0051-4
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center